Advanced Rheumatology — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$56,028	48
2024	Research	$89,279	16
2023	Research	$51,833	3
2022	Research	$33,363	4
2021	Research	$256,650	4
2020	Research	$58,639	6
2019	Research	$49,999	4

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $357,077 10 payments
E.R. Squibb & Sons, L.L.C. $79,063 5 payments
Janssen Research & Development, LLC $60,071 54 payments
Celgene Corporation $50,447 3 payments
Takeda Pharmaceuticals U.S.A., Inc. $30,694 9 payments
Novartis Pharmaceuticals Corporation $18,440 4 payments

Studies the money was for Research payments · program years 2019–2025

Psa-013/20200058 (Keg) (Foremost) $227,087 2 payments
Efficacy Safety Tolerability Study of Apremilast to Treat Early Oligoarticular PSA (PSA-013) $52,221 3 payments
A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or ? 1 Conventional Synthetic DMARD (CC-10004-PSA-013) $49,848 2 payments
DAZ-303 P3 DAZ Efficacy/Safety in SS w/ESSPRI >5 $45,477 1 payment
Phase III PsA #2 - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis (PsA) who are Naive to Biologic Disease Modifying Anti-rhe $37,983 2 payments
Cnto1959psa3004 $34,737 15 payments
Ph4 Otezla in oligoarticular PsA (FOREMOST)/KEG $31,572 2 payments
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 $30,694 9 payments
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) $25,334 39 payments
Phase III PsA #2 (Wk52 driving submission) - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis (PsA) who are Naive to Biologic $23,050 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.